MAIA Biotechnology
View On Demand

Why Regeneron And MAIA Are Taking On Cancer Together

About the Event

MAIA Biotechnology (NYSE: MAIA) and Regeneron are evaluating THIO in sequential administration with Libtayo in a Phase 2 clinical trial for advanced Non-Small Cell Lung Cancer. THIO is a telomere targeting agent that attacks cancer in a whole new way. It is picked up by telomerase and undermines the telomeric structure, killing the 70-90% of the cancer cells in just 24-72 hours. It also creates an immune response so effective that if THIO is followed by a checkpoint inhibitor like Libtayo, it leads to complete response and no recurrence in preclinical trials. It also enables the immune cells to recognize the cancer cells and kill them without any additional therapy. After successfully completing safety studies, the companies are now enrolling and dosing patients in Phase 2 trials to demonstrate the effectiveness of sequential therapy. 

THIO is a platform technology and MAIA currently has 2 programs in progress targeting multiple cancer types in addition to Non-Small Cell Lung Cancer, including Small Cell Lung Cancer, Colorectal, HCC, and other solid tumor cancer indications. They have received 2 orphan drug designations from the FDA. And there are several important milestones approaching including preliminary efficacy data and the initiation of a new basket umbrella study.

Join our webinar with Vlad Vitoc, CEO of MAIA as he shares the latest news on the Phase 2 trial and the company’s other programs.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.